" This financing agreement is an affirmation of our largest stockholders' continued support for our strategy. This funding will provide us with financial flexibility to help us achieve our business objectives," said John Melo, Amyris President & CEO. "Our progress to date developing and manufacturing molecules developed under our proprietary synthetic biology platform, including ramp up of our new industrial fermentation facility for the production of farnesene in Brazil, continues to demonstrate our leadership in the sector ," Melo concluded. PURCHASE TERMS The purchase agreement for the offering contemplates the sale of senior convertible promissory notes in two tranches—one of $35 million in initial principal amount and one of $25 million in initial principal amount. The initial tranche of $35 million is expected to close following stockholder approval at a required special meeting of stockholders, which is scheduled to take place in September.